| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 55.72% | 75.48% | 75.99% | 75.61% | 77.34% | 59.23% | 83.72% | 86.17% | 86.78% | 85.86% | 81.89% | 74.95% |
| Operating Margin | -39.33% | -31.91% | -40.89% | -29.10% | -11.18% | -54.92% | -21.22% | -7.17% | -1.43% | 3.71% | -14.36% | -28.89% |
| EBITDA Margin | -31.83% | -22.61% | -30.20% | -17.94% | -1.09% | -41.86% | -18.56% | -3.72% | 2.01% | 7.83% | -8.41% | -19.61% |
| Net Margin | -36.99% | -38.17% | -42.79% | -35.07% | -16.87% | -53.50% | 6.51% | -7.14% | -0.06% | 3.95% | -51.94% | -26.60% |
| Current Ratio | 4.69 | 5.99 | 5.34 | 6.13 | 7.67 | 9.45 | 4.56 | 5.81 | 5.58 | 7.09 | 5.11 | 0.52 |
| Quick Ratio | 4.06 | 5.22 | 4.78 | 5.61 | 7.31 | 9.13 | 3.82 | 5.38 | 5.16 | 6.68 | 4.91 | 0.41 |
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | 0.10 | -0.11 |
| ROE | -28.60% | -19.09% | -29.16% | -18.72% | -8.45% | -18.03% | 2.29% | -7.45% | -0.07% | 3.86% | -39.12% | 7.54% |
| ROA | -21.01% | -15.02% | -14.32% | -9.90% | -4.72% | -11.97% | 1.88% | -6.26% | -0.06% | 3.37% | -31.92% | -46.60% |
| Asset Turnover | 0.57 | 0.39 | 0.33 | 0.28 | 0.28 | 0.22 | 0.29 | 0.88 | 0.96 | 0.85 | 0.61 | 1.75 |
| Book Value / Share | 11.47 | 14.54 | 9.53 | 11.17 | 12.65 | 15.00 | 16.36 | 4.92 | 4.02 | 3.22 | 5.45 | -70.14 |
Glaukos Corporation is a medical technology company dedicated to the development and commercialization of innovative products for the treatment of glaucoma, corneal disorders, and retinal diseases. Its primary function is to address the substantial unmet medical needs present in ophthalmic healthcare. Glaukos is particularly recognized for pioneering novel micro-invasive glaucoma surgery (MIGS) devices, which are designed to reduce intraocular pressure in glaucoma patients through minimally invasive techniques. The company's product portfolio includes various implantable devices and surgical systems, offering alternatives to traditional invasive surgery and medication. Glaukos Corporation significantly impacts the healthcare industry, especially the ophthalmology sector, by providing solutions that improve patient outcomes and quality of life. Its innovations are crucial in the market, as glaucoma remains one of the leading causes of irreversible blindness globally. By focusing on clinically proven products and expanding its technological reach, Glaukos plays a transformative role in enhancing therapeutic standards and contributing to greater accessibility of advanced eye care treatments.